198 related articles for article (PubMed ID: 22135726)
21. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study.
Vajpayee N; Burack R; Wang D; Hutchison RE; Gajra A
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):159-63. PubMed ID: 25458080
[TBL] [Abstract][Full Text] [Related]
23. Intravascular large B-cell lymphoma presenting as cholecystitis and pancytopenia: case report with literature review.
Duan X; Lapus A; Brown RE; Chen L
Ann Clin Lab Sci; 2011; 41(3):262-6. PubMed ID: 22075510
[TBL] [Abstract][Full Text] [Related]
24. [Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma].
Yu BH; Zhou XY; Xiao XY; Yan SY; Qin T; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):35-41. PubMed ID: 19489223
[TBL] [Abstract][Full Text] [Related]
25. Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects.
Zhang X; Liu Y
CNS Neurol Disord Drug Targets; 2020; 19(3):165-173. PubMed ID: 32416683
[TBL] [Abstract][Full Text] [Related]
26. Diffuse large B-cell lymphoma (DLBCL) with significant intravascular invasion. Close resemblance of its clinicopathological features to intravascular large B-cell lymphoma, but not to DLBCL-not otherwise specified.
Itami H; Nakamine H; Kubo M; Ogawa K; Tani R; Nakamura S; Takeda M; Nitta Y; Uchiyama T; Fujii T; Hatakeyama K; Ohbayashi C
J Clin Exp Hematop; 2021 Sep; 61(3):152-161. PubMed ID: 34193753
[TBL] [Abstract][Full Text] [Related]
27. Intravascular large B-cell lymphoma with cutaneous manifestations: a clinicopathologic, immunophenotypic and molecular study of three cases.
Kong YY; Dai B; Sheng WQ; Yang WT; Wang CF; Kong JC; Shi DR
J Cutan Pathol; 2009 Aug; 36(8):865-70. PubMed ID: 19040469
[TBL] [Abstract][Full Text] [Related]
28. Hemophagocytosis-Related (Asian Variant) Intravascular Large B-Cell Lymphoma in a Hispanic Patient: A Case Report Highlighting a Micronodular Pattern in the Spleen.
Hall JM; Meyers N; Andrews J
Am J Clin Pathol; 2016 May; 145(5):727-35. PubMed ID: 27247375
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
Xu ZZ; Shen JK; Zhao SQ; Li JM
Leuk Lymphoma; 2018 Jun; 59(6):1451-1460. PubMed ID: 28952842
[TBL] [Abstract][Full Text] [Related]
30. Concurrent mycosis fungoides and intravascular large B-cell lymphoma in a single patient.
Goyal A; Totoraitis K; Toama W; He F; Bohjanen K; Williams S; Miller DD
J Cutan Pathol; 2020 Jul; 47(7):643-648. PubMed ID: 32087036
[TBL] [Abstract][Full Text] [Related]
31. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
[TBL] [Abstract][Full Text] [Related]
32. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA
Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954
[TBL] [Abstract][Full Text] [Related]
33. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
34. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.
Murase T; Yamaguchi M; Suzuki R; Okamoto M; Sato Y; Tamaru J; Kojima M; Miura I; Mori N; Yoshino T; Nakamura S
Blood; 2007 Jan; 109(2):478-85. PubMed ID: 16985183
[TBL] [Abstract][Full Text] [Related]
35. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
[TBL] [Abstract][Full Text] [Related]
36. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.
Ezell SA; Wang S; Bihani T; Lai Z; Grosskurth SE; Tepsuporn S; Davies BR; Huszar D; Byth KF
Oncotarget; 2016 Feb; 7(8):9163-74. PubMed ID: 26824321
[TBL] [Abstract][Full Text] [Related]
37. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
[TBL] [Abstract][Full Text] [Related]
38. [Intravascular large B-cell lymphoma: an important cause of fever of unknown origin].
Masaki Y; Miki M; Sakai T; Sawaki T; Fukushima T; Umehara H
Brain Nerve; 2011 May; 63(5):435-41. PubMed ID: 21515922
[TBL] [Abstract][Full Text] [Related]
39. High Frequency of Bone Marrow Involvement in Intravascular Large B-Cell Lymphoma.
Wang J; Ding W; Gao L; Yao W; Chen M; Zhao S; Liu W; Zhang W
Int J Surg Pathol; 2017 Apr; 25(2):118-126. PubMed ID: 27553679
[TBL] [Abstract][Full Text] [Related]
40. Involvement of bone marrow with intravascular large B-cell lymphoma.
Sajid RM; Qureshi A
Hematol Oncol Stem Cell Ther; 2010; 3(1):39-41. PubMed ID: 20231812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
